Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1802]

Immunotherapy developments and new agents for locally advanced NSCLC and SCLC

Dr Edgardo Santos - Florida Precision Oncology, Florida, USA

Immunotherapy developments and new agents for locally advanced NSCLC and SCLC ( Dr Edgardo Santos - Florida Precision Oncology, Florida, USA )

GIST tumours and soft tissue sarcomas

Dr Atif Hussein - Memorial Healthcare System, Florida, USA

GIST tumours and soft tissue sarcomas ( Dr Atif Hussein - Memorial Healthcare System, Florida, USA )

Updates on triple-negative breast cancer and immunotherapy

Dr Avan Armaghani - Moffitt Cancer Center, Tampa, USA

Updates on triple-negative breast cancer and immunotherapy ( Dr Avan Armaghani - Moffitt Cancer Center, Tampa, USA )

Predictive and prognostic biomarkers for immunotherapy in lung cancer

Dr Ignacio Gil Bazo - Fundación Instituto Valenciano de Oncología (FIVO)...

Predictive and prognostic biomarkers for immunotherapy in lung cancer ( Dr Ignacio Gil Bazo - Fundación Instituto Valenciano de Oncología (FIVO), Valencia, Spain )

Immunotherapy in NSCLC: Adjuvant and neoadjuvant clinical scenarios

Dr Luis Raez - Memorial Healthcare System, Florida, USA

Immunotherapy in NSCLC: Adjuvant and neoadjuvant clinical scenarios ( Dr Luis Raez - Memorial Healthcare System, Florida, USA )

Adjuvant nivolumab vs placebo in resected oesophageal or gastroesophageal...

Dr Ronan Kelly - Baylor University Medical Center, Texas, USA

Adjuvant nivolumab vs placebo in resected oesophageal or gastroesophageal junction cancer following chemo: Biomarker analysis ( Dr Ronan Kelly - Baylor University Medical Center, Texas, USA )

Potential benefit to response rates from trastuzumab added to perioperative...

Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of...

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC ( Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force )

Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment

Dr Nausheen Ahmed - The University of Kansas Cancer, Kansas, USA

Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment ( Dr Nausheen Ahmed - The University of Kansas Cancer, Kansas, USA )

Venetoclax and ibrutinib therapy shows favourable results in the treatment of R...

Prof Arnon Kater - Amsterdam UMC, Amsterdam, Netherlands

Venetoclax and ibrutinib therapy shows favourable results in the treatment of R/R chronic lymphocytic leukaemia ( Prof Arnon Kater - Amsterdam UMC, Amsterdam, Netherlands )

Pembrolizumab benefits patients with brain metastases

Dr Priscilla Brastianos - Mass General Cancer Center, Boston, USA

Pembrolizumab benefits patients with brain metastases ( Dr Priscilla Brastianos - Mass General Cancer Center, Boston, USA )

FOLFOX with selective use of 5FUCRT is non-inferior to 5FUCRT for treatment of...

Dr Martin Weiser - Memorial Sloan Kettering Cancer Center, New York City, USA

FOLFOX with selective use of 5FUCRT is non-inferior to 5FUCRT for treatment of LARC prior to low anterior resection with TME ( Dr Martin Weiser - Memorial Sloan Kettering Cancer Center, New York City, USA )

Triplets for newly diagnosed unfit AML patients could be feasible with...

Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain

Triplets for newly diagnosed unfit AML patients could be feasible with substantial venetoclax reduction ( Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain )

More from ecancer